Bionik Laboratories (BNKL) 10-Q2019 Q1 Quarterly report

Filed: 14 Aug 18, 7:31am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: bought, buy, charged, China, clarity, Coghlin, Cogmedix, constant, continuum, cooperative, cumulative, Curexo, device, engineering, enterprise, establish, established, FAS, formally, formation, fulfill, gait, Ginger, History, identification, inclusive, injury, Institute, insufficient, ISO, jointly, JV, knowledge, Korea, Korean, largest, left, magnitude, main, margin, mark, mitigating, monthly, Morning, neuroplasticity, neurorecovery, offset, outsourcing, partnership, People, PRC, Reach, reclassified, reevaluation, reliably, reliance, remediate, rent, repayment, Republic, rewire, sale, Section, segment, service, settlement, source, South, staffing, supplemental, Taiwan, Tech, telephone, Tianjin, turnkey, ultimately, underwritten, USD, version, wearable, website, Wistron, Worchester, world, written

Removed: account, Acquireco, acquirer, added, agent, agreed, Alliance, analyzed, annum, assessed, Assignment, assumed, assumption, assured, attributed, bankrupt, bearing, beneficial, Black, bore, borrowed, Brian, bring, Chinese, choose, closing, collectability, commercialization, Computershare, consolidate, controlling, coverage, declaration, declare, declared, declaring, delivered, designating, dividend, earlier, earliest, economic, equaling, evidence, execution, fixed, force, foregoing, forfeiture, formula, governed, greater, historic, iii, independent, insolvency, insolvent, inspected, instruct, investor, issuable, iv, Jon, lack, lesser, LLC, loaned, Lundgreen, maturity, merged, occurrence, party, pay, perform, persuasive, premium, pricing, promissory, protection, prototyping, Province, quotient, Ray, reallocated, recapitalization, record, redeem, reduction, released, remain, reserving, retained, scientific, secured, securing, security, segregation, shipped, simple, simplified, simultaneously, subordination, subsequently, termination, title, trading, Tungsten, valuator, vote, wound, writing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BNKL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bionik Laboratories Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leslie Markow, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 14, 2018

	/s/ Leslie Markow
	Leslie Markow
	Chief Financial Officer
	(Principal Financial and Accounting Officer)